SlideShare una empresa de Scribd logo
1 de 65
Dose Response Relationship & Therapeutic Index Dr Rizwan
quantal (cumulative) D/R curve tachyphylaxis graded (quantitative) D/R curve therapeutic index potency median toxic dose (TD50) efficacy (effectiveness) median effective dose (ED50) dose/response (D/R) Objectives
[object Object]
Systemic description of the magnitude of the  effect of a drug  as a function of the dose (very low to very high)
Dose response curves ,[object Object]
[object Object],[object Object],[object Object],[object Object]
Shape of the curve ,[object Object],[object Object],[object Object],[object Object],[object Object]
 
Threshold ,[object Object],[object Object]
BIOLOGICAL STIMULUS PERCENT RECEPTOR OCCUPANCY 0% 100% BIOLOGICAL RESPONSE RECEPTOR RESERVE TRETHOLD 0% 100% Max Effect Threshold Effect Schematic representation of the relationship between threshold, receptor  reserve, receptor occupancy, biological stimulus and biological response
 
When a threshold is difficult to determine ,[object Object],Why?
[object Object],[object Object],A  relatively flat slope suggest  that effect of an  increasing dose is  minimal
Dose Response Curve ,[object Object]
 
[object Object],[object Object],[object Object],[object Object]
 
Is there any relationship between shape of curve and potency ,[object Object]
Reason for steep curve ,[object Object],[object Object],[object Object]
 
Used to measure ,[object Object],[object Object],[object Object]
POTENCY CONCENTRATION (EC50) OR DOSE (ED50)  OF A DRUG  REQUIRED TO PRODUCE  50% OF THAT DRUG’S MAXIMUM EFFECT
X 0 Average  Response  Magnitude DRUG DOSE Potency HI ,[object Object],A B
DRUG DOSE X 0 Average  Response  Magnitude HI LO Maximum Efficacy ,[object Object],A B
[D] (concentration units) % Maximal Effect 0.01 0.10 1.00 10.00 100.00 1000.00 0.0 0.2 0.4 0.6 0.8 1.0 Partial agonist Full Agonist Partial agonist PARTIAL AGONISTS - EFFICACY Even though drugs may occupy the same # of receptors, the magnitude of their effects may differ.
 
 
Example  ,[object Object],BUT
[object Object],[object Object]
Difference between the 3 drugs is their   ,[object Object],ISOPROTERENOL  >  EPINEPHRINE  >  NOR EPINEPHRINE
[object Object],[object Object],[object Object]
What is the difference between Quantal and graded dose-response curves?
Graded (Quantitative) dose-effect relationships   ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Graded dose response curves show effects  on a continuous scale And the intensity of the effect  is proportional to the dose
Exposure to ethanol  Graded responses between no effect and death
Requirements   ,[object Object],[object Object]
Problem   ,[object Object]
Plot of the contraction of the intestinal smooth muscle in response to varied doses of acetylcholine
Observation   ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Quantal (All-or-none; binary) dose-effect relationships   ,[object Object],[object Object]
All or None ,[object Object],[object Object],[object Object],[object Object]
 
Purpose   ,[object Object]
Defined specific effect and degree of response  -- ,[object Object],[object Object],[object Object],[object Object]
Problem   ,[object Object],[object Object]
Titration   ,[object Object],[object Object],[object Object],[object Object]
Titration of each individual  Administer increasing doses of drug to each individual until a response is elicited, then note the dose.  Do this for all members of the test population.  very impractical  ------serious conceptual disadvantages,  e.g., multiple doses of drug may produce a false effect compared to a single exposure to a larger dose.  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Shape of curve   ,[object Object],[object Object]
Description of data   ,[object Object]
Construction of  quantal  (binary) dose-effect curves   ,[object Object],[object Object]
Method A: Titrate each animal   Sample experiment ,[object Object],[object Object],[object Object],[object Object],[object Object]
BELL SHAPED CURVE majority of responders in the middle mean response is approx. 110 mg/kg fewer responders at the end of bell curve (expected) known as  biological variability responders at the far left of the mean are typically  hypersusceptible whereas those at the far right are  resistant
Comments   ,[object Object],[object Object],[object Object]
Method B -- Titration of groups ,[object Object],[object Object]
Sample experiment  ,[object Object],[object Object],[object Object],[object Object],[object Object]
Cumulative quantal dose response plot
 
Both curves provide ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Quantal D/R curves  used to define  ,[object Object],[object Object],[object Object]
 
 
[object Object],[object Object],[object Object],Decision Making ,[object Object],[object Object],[object Object],LD 50 ED 50
BIOLOGICAL STIMULUS PERCENT RECEPTOR OCCUPANCY 0% 100% BIOLOGICAL RESPONSE RECEPTOR RESERVE TRETHOLD 0% 100% Max Effect Threshold Effect Schematic representation of the relationship between threshold, receptor  reserve, receptor occupancy, biological stimulus and biological response
[object Object],100 50 0 DRUG DOSE 0 X ED LD % subjects TI = LD 50 / ED 50
[object Object],100 50 0 DRUG DOSE 0 X ED LD % subjects TI = LD 50 / ED 50

Más contenido relacionado

La actualidad más candente

Receptor Pharmacology
Receptor PharmacologyReceptor Pharmacology
Receptor Pharmacology
Tulasi Raman
 
Clinical Pharmacokinetics-I [half life, order of kinetics, steady state]
Clinical Pharmacokinetics-I [half life, order of kinetics, steady state]Clinical Pharmacokinetics-I [half life, order of kinetics, steady state]
Clinical Pharmacokinetics-I [half life, order of kinetics, steady state]
BADAR UDDIN UMAR
 
Factors modifying drug action, efficacy & potency
Factors modifying drug action, efficacy & potencyFactors modifying drug action, efficacy & potency
Factors modifying drug action, efficacy & potency
BADAR UDDIN UMAR
 
2. dose resp relationsp presentsn copy - copy
2. dose resp relationsp presentsn   copy - copy2. dose resp relationsp presentsn   copy - copy
2. dose resp relationsp presentsn copy - copy
suniu
 

La actualidad más candente (20)

Therapeutic Index of drugs and Factors modifying drug action
Therapeutic Index of drugs and Factors modifying drug action Therapeutic Index of drugs and Factors modifying drug action
Therapeutic Index of drugs and Factors modifying drug action
 
Receptor Pharmacology
Receptor PharmacologyReceptor Pharmacology
Receptor Pharmacology
 
Principles of toxicology
Principles of toxicologyPrinciples of toxicology
Principles of toxicology
 
Drug receptor interactions and types of receptor
Drug receptor interactions and types of receptorDrug receptor interactions and types of receptor
Drug receptor interactions and types of receptor
 
Dose response relationship
Dose response relationshipDose response relationship
Dose response relationship
 
Toxicology
ToxicologyToxicology
Toxicology
 
Spare receptors
Spare receptorsSpare receptors
Spare receptors
 
Clinical Pharmacokinetics-I [half life, order of kinetics, steady state]
Clinical Pharmacokinetics-I [half life, order of kinetics, steady state]Clinical Pharmacokinetics-I [half life, order of kinetics, steady state]
Clinical Pharmacokinetics-I [half life, order of kinetics, steady state]
 
Basic definition and types of toxicology
Basic definition and types of toxicologyBasic definition and types of toxicology
Basic definition and types of toxicology
 
Dose response relationship
Dose response relationshipDose response relationship
Dose response relationship
 
ACUTE, SUB ACUTE & CHRONIC TOXICOLOGICAL STUDIES
ACUTE, SUB ACUTE & CHRONIC TOXICOLOGICAL STUDIESACUTE, SUB ACUTE & CHRONIC TOXICOLOGICAL STUDIES
ACUTE, SUB ACUTE & CHRONIC TOXICOLOGICAL STUDIES
 
Factors modifying drug action, efficacy & potency
Factors modifying drug action, efficacy & potencyFactors modifying drug action, efficacy & potency
Factors modifying drug action, efficacy & potency
 
Quantitative aspects of drug receptor interaction
Quantitative aspects of drug receptor interactionQuantitative aspects of drug receptor interaction
Quantitative aspects of drug receptor interaction
 
Bioassay
BioassayBioassay
Bioassay
 
2. dose resp relationsp presentsn copy - copy
2. dose resp relationsp presentsn   copy - copy2. dose resp relationsp presentsn   copy - copy
2. dose resp relationsp presentsn copy - copy
 
Dose response relationship
Dose response relationshipDose response relationship
Dose response relationship
 
Types of receptors
Types of receptorsTypes of receptors
Types of receptors
 
Dose response curvevpp
Dose response curvevppDose response curvevpp
Dose response curvevpp
 
Toxicology- Scope and Principles
Toxicology- Scope and PrinciplesToxicology- Scope and Principles
Toxicology- Scope and Principles
 
Combined effect of Drugs
Combined effect of Drugs Combined effect of Drugs
Combined effect of Drugs
 

Similar a Lecture 2 Dose Response Relationship 1

Similar a Lecture 2 Dose Response Relationship 1 (20)

DRC.pdf
DRC.pdfDRC.pdf
DRC.pdf
 
Dose Response Phenomenon.pptx
Dose Response Phenomenon.pptxDose Response Phenomenon.pptx
Dose Response Phenomenon.pptx
 
bioassay.pdf
bioassay.pdfbioassay.pdf
bioassay.pdf
 
Bioassay ppt by dr sumit
Bioassay ppt by dr sumitBioassay ppt by dr sumit
Bioassay ppt by dr sumit
 
Determination of potency metronidazole
Determination of potency metronidazoleDetermination of potency metronidazole
Determination of potency metronidazole
 
Unit 10 +11 dose response relationship (PC- 520)
Unit 10 +11 dose response relationship (PC- 520)Unit 10 +11 dose response relationship (PC- 520)
Unit 10 +11 dose response relationship (PC- 520)
 
Dose Response Curve
Dose Response CurveDose Response Curve
Dose Response Curve
 
BIOASSAYS.pptx
BIOASSAYS.pptxBIOASSAYS.pptx
BIOASSAYS.pptx
 
Consequences of drug receptor interactions
Consequences of drug receptor interactionsConsequences of drug receptor interactions
Consequences of drug receptor interactions
 
branch of pharmacology dedicated to determine the fate of substances administ...
branch of pharmacology dedicated to determine the fate of substances administ...branch of pharmacology dedicated to determine the fate of substances administ...
branch of pharmacology dedicated to determine the fate of substances administ...
 
Pharmacodynamics.2020
Pharmacodynamics.2020Pharmacodynamics.2020
Pharmacodynamics.2020
 
Pharmacodynamics 2020
Pharmacodynamics 2020 Pharmacodynamics 2020
Pharmacodynamics 2020
 
Overview of Pharmacodynamics
Overview of PharmacodynamicsOverview of Pharmacodynamics
Overview of Pharmacodynamics
 
Bioassay.pptx
Bioassay.pptxBioassay.pptx
Bioassay.pptx
 
bioassay-converted.pptx
bioassay-converted.pptxbioassay-converted.pptx
bioassay-converted.pptx
 
Dose-Response of drugs towards the human body
Dose-Response of drugs towards the human bodyDose-Response of drugs towards the human body
Dose-Response of drugs towards the human body
 
Expt. 4 DRC of acetylcholine using frog rectus abdominis muscle
Expt. 4 DRC of acetylcholine using frog rectus abdominis muscleExpt. 4 DRC of acetylcholine using frog rectus abdominis muscle
Expt. 4 DRC of acetylcholine using frog rectus abdominis muscle
 
Ic50
Ic50Ic50
Ic50
 
Bioassay
BioassayBioassay
Bioassay
 
Lecture 1 Pharmacodynamics
Lecture 1 PharmacodynamicsLecture 1 Pharmacodynamics
Lecture 1 Pharmacodynamics
 

Más de Dr Shah Murad (20)

Directory and other informat
Directory and other informatDirectory and other informat
Directory and other informat
 
Chemo mcq's
Chemo mcq'sChemo mcq's
Chemo mcq's
 
Corticosteroids
CorticosteroidsCorticosteroids
Corticosteroids
 
Cv my august in another format
Cv my august in another formatCv my august in another format
Cv my august in another format
 
My article pubmed
My article pubmedMy article pubmed
My article pubmed
 
Http for songs
Http for songsHttp for songs
Http for songs
 
Hyperstar
HyperstarHyperstar
Hyperstar
 
My Personal Phone Directory
 My Personal Phone Directory My Personal Phone Directory
My Personal Phone Directory
 
My Research Article
My Research ArticleMy Research Article
My Research Article
 
Resume of PROF DR SHAH MURAD jan 2011
Resume of PROF DR SHAH MURAD jan 2011Resume of PROF DR SHAH MURAD jan 2011
Resume of PROF DR SHAH MURAD jan 2011
 
Hasnain Hakro pics
Hasnain Hakro picsHasnain Hakro pics
Hasnain Hakro pics
 
Intro to pharmacology
Intro to pharmacologyIntro to pharmacology
Intro to pharmacology
 
Cv my dec 2010
Cv my dec 2010Cv my dec 2010
Cv my dec 2010
 
Friendz pics
Friendz picsFriendz pics
Friendz pics
 
My Pictures
My PicturesMy Pictures
My Pictures
 
Hasnain Hakro
Hasnain HakroHasnain Hakro
Hasnain Hakro
 
Cv my nov 2010
Cv my nov 2010Cv my nov 2010
Cv my nov 2010
 
RESUME OF PROF. DR. SHAH MURAD
RESUME OF PROF. DR. SHAH MURADRESUME OF PROF. DR. SHAH MURAD
RESUME OF PROF. DR. SHAH MURAD
 
CV of Prof. Dr. Shah Murad
CV of Prof. Dr. Shah MuradCV of Prof. Dr. Shah Murad
CV of Prof. Dr. Shah Murad
 
Antihyperlipidemics2
Antihyperlipidemics2Antihyperlipidemics2
Antihyperlipidemics2
 

Último

Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024
Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024
Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024
Victor Rentea
 
Why Teams call analytics are critical to your entire business
Why Teams call analytics are critical to your entire businessWhy Teams call analytics are critical to your entire business
Why Teams call analytics are critical to your entire business
panagenda
 

Último (20)

Polkadot JAM Slides - Token2049 - By Dr. Gavin Wood
Polkadot JAM Slides - Token2049 - By Dr. Gavin WoodPolkadot JAM Slides - Token2049 - By Dr. Gavin Wood
Polkadot JAM Slides - Token2049 - By Dr. Gavin Wood
 
ICT role in 21st century education and its challenges
ICT role in 21st century education and its challengesICT role in 21st century education and its challenges
ICT role in 21st century education and its challenges
 
Apidays New York 2024 - APIs in 2030: The Risk of Technological Sleepwalk by ...
Apidays New York 2024 - APIs in 2030: The Risk of Technological Sleepwalk by ...Apidays New York 2024 - APIs in 2030: The Risk of Technological Sleepwalk by ...
Apidays New York 2024 - APIs in 2030: The Risk of Technological Sleepwalk by ...
 
Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024
Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024
Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024
 
How to Troubleshoot Apps for the Modern Connected Worker
How to Troubleshoot Apps for the Modern Connected WorkerHow to Troubleshoot Apps for the Modern Connected Worker
How to Troubleshoot Apps for the Modern Connected Worker
 
Artificial Intelligence Chap.5 : Uncertainty
Artificial Intelligence Chap.5 : UncertaintyArtificial Intelligence Chap.5 : Uncertainty
Artificial Intelligence Chap.5 : Uncertainty
 
Strategize a Smooth Tenant-to-tenant Migration and Copilot Takeoff
Strategize a Smooth Tenant-to-tenant Migration and Copilot TakeoffStrategize a Smooth Tenant-to-tenant Migration and Copilot Takeoff
Strategize a Smooth Tenant-to-tenant Migration and Copilot Takeoff
 
Ransomware_Q4_2023. The report. [EN].pdf
Ransomware_Q4_2023. The report. [EN].pdfRansomware_Q4_2023. The report. [EN].pdf
Ransomware_Q4_2023. The report. [EN].pdf
 
MINDCTI Revenue Release Quarter One 2024
MINDCTI Revenue Release Quarter One 2024MINDCTI Revenue Release Quarter One 2024
MINDCTI Revenue Release Quarter One 2024
 
Axa Assurance Maroc - Insurer Innovation Award 2024
Axa Assurance Maroc - Insurer Innovation Award 2024Axa Assurance Maroc - Insurer Innovation Award 2024
Axa Assurance Maroc - Insurer Innovation Award 2024
 
AXA XL - Insurer Innovation Award Americas 2024
AXA XL - Insurer Innovation Award Americas 2024AXA XL - Insurer Innovation Award Americas 2024
AXA XL - Insurer Innovation Award Americas 2024
 
Corporate and higher education May webinar.pptx
Corporate and higher education May webinar.pptxCorporate and higher education May webinar.pptx
Corporate and higher education May webinar.pptx
 
Why Teams call analytics are critical to your entire business
Why Teams call analytics are critical to your entire businessWhy Teams call analytics are critical to your entire business
Why Teams call analytics are critical to your entire business
 
Manulife - Insurer Transformation Award 2024
Manulife - Insurer Transformation Award 2024Manulife - Insurer Transformation Award 2024
Manulife - Insurer Transformation Award 2024
 
Rising Above_ Dubai Floods and the Fortitude of Dubai International Airport.pdf
Rising Above_ Dubai Floods and the Fortitude of Dubai International Airport.pdfRising Above_ Dubai Floods and the Fortitude of Dubai International Airport.pdf
Rising Above_ Dubai Floods and the Fortitude of Dubai International Airport.pdf
 
presentation ICT roal in 21st century education
presentation ICT roal in 21st century educationpresentation ICT roal in 21st century education
presentation ICT roal in 21st century education
 
Web Form Automation for Bonterra Impact Management (fka Social Solutions Apri...
Web Form Automation for Bonterra Impact Management (fka Social Solutions Apri...Web Form Automation for Bonterra Impact Management (fka Social Solutions Apri...
Web Form Automation for Bonterra Impact Management (fka Social Solutions Apri...
 
Boost Fertility New Invention Ups Success Rates.pdf
Boost Fertility New Invention Ups Success Rates.pdfBoost Fertility New Invention Ups Success Rates.pdf
Boost Fertility New Invention Ups Success Rates.pdf
 
"I see eyes in my soup": How Delivery Hero implemented the safety system for ...
"I see eyes in my soup": How Delivery Hero implemented the safety system for ..."I see eyes in my soup": How Delivery Hero implemented the safety system for ...
"I see eyes in my soup": How Delivery Hero implemented the safety system for ...
 
FWD Group - Insurer Innovation Award 2024
FWD Group - Insurer Innovation Award 2024FWD Group - Insurer Innovation Award 2024
FWD Group - Insurer Innovation Award 2024
 

Lecture 2 Dose Response Relationship 1

  • 1. Dose Response Relationship & Therapeutic Index Dr Rizwan
  • 2. quantal (cumulative) D/R curve tachyphylaxis graded (quantitative) D/R curve therapeutic index potency median toxic dose (TD50) efficacy (effectiveness) median effective dose (ED50) dose/response (D/R) Objectives
  • 3.
  • 4. Systemic description of the magnitude of the effect of a drug as a function of the dose (very low to very high)
  • 5.
  • 6.
  • 7.
  • 8.  
  • 9.
  • 10. BIOLOGICAL STIMULUS PERCENT RECEPTOR OCCUPANCY 0% 100% BIOLOGICAL RESPONSE RECEPTOR RESERVE TRETHOLD 0% 100% Max Effect Threshold Effect Schematic representation of the relationship between threshold, receptor reserve, receptor occupancy, biological stimulus and biological response
  • 11.  
  • 12.
  • 13.
  • 14.
  • 15.  
  • 16.
  • 17.  
  • 18.
  • 19.
  • 20.  
  • 21.
  • 22. POTENCY CONCENTRATION (EC50) OR DOSE (ED50) OF A DRUG REQUIRED TO PRODUCE 50% OF THAT DRUG’S MAXIMUM EFFECT
  • 23.
  • 24.
  • 25. [D] (concentration units) % Maximal Effect 0.01 0.10 1.00 10.00 100.00 1000.00 0.0 0.2 0.4 0.6 0.8 1.0 Partial agonist Full Agonist Partial agonist PARTIAL AGONISTS - EFFICACY Even though drugs may occupy the same # of receptors, the magnitude of their effects may differ.
  • 26.  
  • 27.  
  • 28.
  • 29.
  • 30.
  • 31.
  • 32. What is the difference between Quantal and graded dose-response curves?
  • 33.
  • 34. Graded dose response curves show effects on a continuous scale And the intensity of the effect is proportional to the dose
  • 35. Exposure to ethanol Graded responses between no effect and death
  • 36.
  • 37.
  • 38. Plot of the contraction of the intestinal smooth muscle in response to varied doses of acetylcholine
  • 39.
  • 40.
  • 41.
  • 42.  
  • 43.
  • 44.
  • 45.
  • 46.
  • 47.
  • 48.
  • 49.
  • 50.
  • 51.
  • 52. BELL SHAPED CURVE majority of responders in the middle mean response is approx. 110 mg/kg fewer responders at the end of bell curve (expected) known as biological variability responders at the far left of the mean are typically hypersusceptible whereas those at the far right are resistant
  • 53.
  • 54.
  • 55.
  • 56. Cumulative quantal dose response plot
  • 57.  
  • 58.
  • 59.
  • 60.  
  • 61.  
  • 62.
  • 63. BIOLOGICAL STIMULUS PERCENT RECEPTOR OCCUPANCY 0% 100% BIOLOGICAL RESPONSE RECEPTOR RESERVE TRETHOLD 0% 100% Max Effect Threshold Effect Schematic representation of the relationship between threshold, receptor reserve, receptor occupancy, biological stimulus and biological response
  • 64.
  • 65.